Jeffrey Lawson
Oprichter bij InnAVasc Medical, Inc.
Actieve functies van Jeffrey Lawson
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Humacyte Global, Inc.
Humacyte Global, Inc. Medical SpecialtiesHealth Technology Humacyte Global, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. It offers its products to the cardiovascular, cosmetic, soft tissue reconstruction, neurosurgical, and orthopedic markets. The company was founded by Laura E. Niklason, Juliana L. Blum and Shannon L. M. Dahl in 2004 and is headquartered in Durham, NC. | Directeur/Bestuurslid | 01-07-2018 | - |
Corporate Officer/Principal | 20-11-2020 | - | |
Algemeen Directeur | 01-06-2018 | 20-11-2020 | |
Hoofd Techniek/Wetenschap/O&O | 01-01-2015 | - | |
President | 01-01-2018 | 20-11-2020 | |
InnAVasc Medical, Inc.
InnAVasc Medical, Inc. Medical SpecialtiesHealth Technology InnAVasc Medical, Inc. designs and develops products for vascular access for hemodialysis. Its technology vascular access graft is designed to create one contiguous flow lumen without transition points. The company is headquartered in Durham, NC. | Directeur/Bestuurslid | 13-05-2013 | - |
Oprichter | 13-05-2013 | - | |
Kidney Health Initiative | Directeur/Bestuurslid | - | - |
Vascular Access Society of The Americas | Directeur/Bestuurslid | - | - |
Foundation For Women & Girls With Blood Disorders | Directeur/Bestuurslid | - | - |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Algemeen Directeur | 12-10-2023 | - |
Loopbaan van Jeffrey Lawson
Eerdere bekende functies van Jeffrey Lawson
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
HUMACYTE, INC. | Directeur/Bestuurslid | 26-08-2021 | 31-12-2021 |
Corporate Officer/Principal | 26-08-2021 | 31-12-2021 |
Opleiding van Jeffrey Lawson
University of Vermont College of Medicine | Doctorate Degree |
Statistieken
Internationaal
Verenigde Staten | 8 |
Nederland | 2 |
Operationeel
Director/Board Member | 6 |
Chief Executive Officer | 2 |
Corporate Officer/Principal | 2 |
Sectoraal
Health Technology | 5 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
HUMACYTE, INC. | Health Technology |
Bedrijven in privébezit | 6 |
---|---|
Humacyte Global, Inc.
Humacyte Global, Inc. Medical SpecialtiesHealth Technology Humacyte Global, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. It offers its products to the cardiovascular, cosmetic, soft tissue reconstruction, neurosurgical, and orthopedic markets. The company was founded by Laura E. Niklason, Juliana L. Blum and Shannon L. M. Dahl in 2004 and is headquartered in Durham, NC. | Health Technology |
InnAVasc Medical, Inc.
InnAVasc Medical, Inc. Medical SpecialtiesHealth Technology InnAVasc Medical, Inc. designs and develops products for vascular access for hemodialysis. Its technology vascular access graft is designed to create one contiguous flow lumen without transition points. The company is headquartered in Durham, NC. | Health Technology |
Kidney Health Initiative | |
Vascular Access Society of The Americas | |
Foundation For Women & Girls With Blood Disorders | |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Health Technology |
- Beurs
- Insiders
- Jeffrey Lawson
- Ervaring